INSUBCONTINENT EXCLUSIVE:
A little over a year after the dissolution of the once high-flying blood testing startup Theranos, another startup has raised more than $27
million to breathe new life into the vision of bringing low-cost blood tests to point-of-care medical facilities.Unlike Theranos, Truvian
Sciences is not claiming that most of its blood tests do not need clearance from the U.S
Food and Drug Administration, and is, in fact, raising the money to proceed with a year-long process to refine its technology and submit it
By bringing accurate, on-site blood testing to convenient sites, we will give consumers a more seamless experience and enable them to act on
genetic health business at Illumina, is joined by a seasoned executive team of life sciences professionals, including Dr
Sciences and Illumina, as its new chief commercial officer, and has brought on the former chairman of the Thermo Fisher Scientific board of
Partners and previous investor Domain Associates.The ultimate goal, according to Hawkins, is to develop a system that can be installed in
labs and can in 20 minutes and for as low as $50 provide from a small sample of blood accurate results for a battery of health tests
Hawkins.Using new automation and sensing technologies, Truvian is aiming to combine chemistries, immunoassays and hematology assays into a
single device that can perform standard assessment blood tests like lipid panels, metabolic panels, blood cell counts and tests of thyroid,
Its dry reagent technology allows materials to be stored at room temperature, removing the need for cold chain or refrigerated storage
According to a statement, the company is working to receive a CE Mark in the European Economic Area and submitted to the FDA for 510(k)
